Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the selective and progressive loss of motor neurons. Although many drugs have entered clinical trials, few have shown effectiveness in the treatment of ALS. Other studies have shown that the stimulation of α7 nicotinic acetylcholine receptor (nAChR) can have neuroprotective effects in some models of neurodegenerative disease, as well as prevent glutamate-induced motor neuronal death. However, the effect of α7 nAChR agonists on ALS-associated mutant copper–zinc superoxide dismutase 1 (SOD1) aggregates in motor neurons remains unclear. In the present study, we examined whether α7 nAChR activation had a neuroprotective effect against SOD1G85R-induced toxicity in a cellular model for ALS. We found that α7 nAChR activation by PNU282987, a selective agonist of α7 nAChR, exhibited significant neuroprotective effects against SOD1G85R-induced toxicity via the reduction of intracellular protein aggregates. This reduction also correlated with the activation of autophagy through the AMP-activated protein kinase (AMPK)–mammalian target of rapamycin (mTOR) signaling pathway. Furthermore, the activation of α7 nAChRs was found to increase the biogenesis of lysosomes by inducing translocation of the transcription factor EB (TFEB) into the nucleus. These results support the therapeutic potential of α7 nAChR activation in diseases that are characterized by SOD1G85R aggregates, such as ALS.
Amyotrophic lateral sclerosis (ALS) is a neuromuscular degenerative disorder characterized by the selective and progressive loss of motor neurons. ALS patients experience motor weakness, which starts focally and spreads throughout the nervous system and dies within a few years of diagnosis. While the majority of clinical ALS is sporadic, mutation copper-zinc superoxide dismutase 1 (SOD1) cause about 20 % of familial ALS (FALS). ALS with mutant SOD1 is caused by a toxic gain of function associated with the propensity of misfolding SOD1. The motor neurons in ALS patients are known to be formation of intracellular protein aggregate that are caused by mutations in the SOD1 gene. Kaempferol is a phytoestrogen found in a variety of vegetables and fruits, such as tomatoes, hops, red grapes, and strawberries. Kaempferol has been used in traditional medicine and is believed to have various biological functions. The purpose of this study was to clarify effects of kaempferol against ALS-associated mutant SOD1-induced neurotoxicity. We examine whether kaempferol and kaempferide, a derivative of kaempferol, have neuroprotective effect against mutant SOD1induced neurotoxicity in a cellular model. Kaempferol and kaempferide inhibited mutant SOD1-induced cell death and reduced the intracellular mutant SOD1 aggregates. Both kaempferol and kaempferide significantly suppressed mutant SOD1-induced superoxide in mitochondria. To examine the mechanism, which reducing the number of intracellular aggregate, we focused on autophagy, a major pathway for the elimination of aggregated-proteins and damaged-organelles. Western blot analysis showed that kaempferol, but not kaempferide, promote the formation of LC3-II, indicating the upregulation of autophagy. To identify the signal transduction pathway mediated by kaempferol, we examined the following pathways that regulate the mammalian target of rapamycin (mTOR) activity. Kaempferol induced autophagy via the AMP-activated protein kinase (AMPK)-mTOR pathway. These results suggest that kaempferol against mutant SOD1-mediated neurotoxicity will be an efficient source of new treatments and prevention for ALS.
BackgroundAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the selective and progressive loss of motor neurons. Although many drugs have entered clinical trials, few have shown effectiveness in the treatment of ALS. Previous studies searching for causal genes associated with familial ALS identified the copper-zinc superoxide dismutase 1 (SOD1). Other studies have shown that the stimulation of α7 nicotinic acetylcholine receptor (nAChR) can have neuroprotective effects in some models of neurodegenerative disease, as well as prevent glutamate-induced motor neuronal death. However, the effect of α7 nAChR agonists on mutant SOD1 aggregates in motor neurons remains unclear.MethodsWe examined whether α7 nAChR activation had a neuroprotective effect against SOD1G85R-induced toxicity in a cellular model for ALS. Furthermore, the mechanism was also examined by Western blot analysis and qRT-PCR.ResultsWe found that α7 nAChR activation showed significant neuroprotective effects against SOD1G85R-induced toxicity via the reduction of intracellular protein aggregates. This reduction also correlated with the activation of autophagy through the AMP-activated protein kinase (AMPK)–mammalian target of rapamycin (mTOR) signaling pathway. Furthermore, the activation of α7 nAChRs was found to increase the biogenesis of lysosomes by inducing translocation of the transcription factor EB (TFEB) into the nucleus.ConclusionsThese results support the therapeutic potential of α7 nAChR activation in diseases that are characterized by SOD1G85R aggregates, such as ALS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.